Document:

EX-4.(a)(iv)

 Exhibit 4(a)(iv) 

AMENDMENT TO THE TRANSACTION AGREEMENT 
 This AMENDMENT TO THE TRANSACTION AGREEMENT (this “Amendment”), dated as of December 21, 2012, by and between DFB Pharmaceuticals, Inc., a Texas corporation (“Seller
Parent”), and Smith & Nephew, Inc., a Delaware corporation (“Buyer Domestic”). 

WHEREAS, Seller Parent, Buyer Domestic, Smith & Nephew Inc., a Canada corporation, Smith & Nephew, Inc., a
Puerto Rican corporation, Smith & Nephew Orthopaedics AG, a limited company incorporated under the laws of Switzerland, Sudbury Acquisitions N.V., a Curaçao limited liability company, Healthpoint, Ltd., a Texas limited partnership
(“Healthpoint”), Healthpoint International, LLC, a Texas limited liability company, DFB Biotech of Curaçao, N.V., a limited liability company incorporated under the laws of the Netherland Antilles and existing under the laws
of Curaçao, and Healthpoint Canada ULC, a Nova Scotia Unlimited Liability Corporation are parties to that certain Transaction Agreement dated as of November 27, 2012 (the “Transaction Agreement”), providing for the
acquisition of the Purchased Assets and assumption of the Assumed Liabilities by the Buyer Parties; and 
 WHEREAS, the
parties desire to amend the Transaction Agreement as provided in this Amendment in accordance with Section 14.02 of the Transaction Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties and agreements contained in this Amendment, and intending to be legally bound, Seller Parent and Buyer Domestic
hereby agree as follows: 
 1. The defined term “State FCA Settlement Amount” in Section 1.01 of the Transaction Agreement is
hereby amended and restated to read in its entirety as follows: 
 “State FCA Settlement Amount” means an
aggregate amount equal to $***, which amount is to be used to pay costs of settlement of the False Claims Act Litigation with each state of the United States and the District of Columbia, with $*** of such amount established based upon the share of
the state portion of the total settlement as proposed by the National Association of Medicaid Fraud Control Units (“NAMFCU”) with respect to the states whose attorneys have indicated they will recommend executing the FCA State Template
Settlement Agreement and $*** of such amount determined in accordance with the methodology set forth on Schedule 1.01(h). 
 2. Sections 2.01(1)
and (m) of the Transaction Agreement shall be amended and restated in their entirety as set forth below and an additional Section 2.01(n) shall be added as set forth below: 

(l) all transferable Permits, including Environmental Permits; 
 (m) all goodwill associated with the Business; and 

  

	***	Material has been omitted pursuant to a request for confidential treatment and has been filed separately. 

 (n) to the extent transferable, all of the bank accounts of Healthpoint listed in Schedule
2.01(n); provided, that the transfer of ownership of such bank accounts shall not occur until Buyer Domestic has notified Sellers in writing that the Parties’ regulatory obligations under the Transition Services Agreement and obligations under
the Subcontract have been discharged to the parties’ reasonable satisfaction and such agreements have been terminated or have expired by their terms. 
 3. Section 2.02(i) of the Transaction Agreement shall be amended and restated in its entirety as set forth below: 
 (i) all bank accounts, whether or not used in the Business, other than those described in Section 2.01(n). 
 4. Section 6.13 of the Transaction Agreement shall be amended and restated in its entirety as set forth below: 
 Section 6.13. Name Change. Promptly upon request by Buyer Domestic, and assuming such actions would not materially interfere with (a) the performance of the Sellers of their obligations
under the Subcontract or the Transition Services Agreement (or the applicable Buyer Parties have waived any nonperformance resulting from such actions) or (b) the Sellers’ performance of any reporting obligations to Governmental
Authorities relating thereto, the Sellers shall, and shall cause their applicable Affiliates to, change their respective entity names to a name that does not contain (and that is not confusingly similar to) the name “Healthpoint.” Promptly
following the Closing, and in any event no later than 15 days following the Closing Date, the Sellers shall use commercially reasonable efforts, at Buyer Domestic’s expense, to assist Buyer Domestic in obtaining the rights to operate under
the assumed name “Healthpoint Biotherapeutics” (including revoking or withdrawing any existing assumed name filings with respect to such name and, if necessary, providing letters of consent regarding the same to any applicable Governmental
Authorities). From and after the Closing, (i) Sellers shall not, directly or indirectly, use and shall not license or authorize any third party to use any name, slogan, logo or trademark which is similar or deceptively similar to any of the
trademarks or any other name used in connection with the Business; and (ii) Sellers shall not use the names “Healthpoint” and “Healthpoint Biotherapeutics” in any manner that would constitute misuse, impairment,
disparagement or dilution of such names or the goodwill associated with one or more of such names and shall not operate any business under the names “Healthpoint” and “Healthpoint Biotherapeutics” except to provide any transition
services to the Buyer Parties in accordance with the Transition Services Agreement. 
 5. Section 6.10(b) of the Transaction Agreement is
hereby amended and restated to read in its entirety as follows: 
 “(b) Each Seller shall cause each signatory to the
Seller FDA Letter to duly execute the Seller FDA Letter as soon as all required information is available, but in no event later than thirty (30) days following the Closing Date.” 

 6. The following Section 12.03(h) shall be added to the Transaction Agreement: 

“(h) The foregoing procedures set forth in this Section 12.03 shall not apply to the *** Litigation, which shall be governed by
Section 7.07 and the Joint Defense Agreement referenced therein.” 
 7. Section 12.07(b) of the Transaction Agreement is hereby
amended to read in its entirety as follows: “(b) Intentionally Omitted.” 
 8. Section 12.07(c) is hereby amended and restated to
read in its entirety as follows: 
 “(c) Following the Closing, Buyer Domestic and the Sellers shall, upon the entry into a
settlement with any state or the entry of a final, non-appealable judgment with respect to the pending False Claims Act Litigation relating to such state, take all necessary actions to cause (i) the prompt release from the Escrow Account of any
amounts due to such state (up to the amount of the State FCA Settlement Amount remaining in the Escrow Account), (ii) the payment, on behalf of Sellers, of such amounts directly to the applicable state and (iii) the release to Sellers of
an amount equal to the excess (up to the amount of the State FCA Settlement Amount remaining in the Escrow Account), if any, of (A) the amount set forth opposite such state’s name in the column entitled “State Settlement Share”
for those states listed as “States Recommending Settlement” or the column entitled “Escrow Amount” for those states listed as “States Not Recommending Settlement” on Schedule 12.07(c) over (B) the amount required
to be released from the Escrow Account and paid to such state in accordance with clauses (i) and (ii); provided, however, that the release of any amounts described in clause (iii) of this sentence shall not be made until such
time as the pending False Claims Act Litigation relating to the State of *** has been finally resolved through settlement or through the entry of a final, non-appealable judgment, and any releases pursuant to clause (iii) shall be reduced by an
amount equal to the excess, if any, of the amounts due to the State of Indiana in connection with such resolution over the amount set forth opposite Indiana’s name in the column entitled “Escrow Amount” on Schedule 12.07(c). Buyer
Domestic and Sellers shall take all necessary actions to cause the prompt release from the Escrow Account of any amounts (up to the amount of the State FCA Settlement Amount remaining in the Escrow Account) allocated to any state listed as
“States Who Have Not Yet Provided Notification Regarding Recommendation of Settlement” that has not commenced a Xenaderm-related action within *** following the Closing Date.” 
 9. Section 12.07(e) of the Transaction Agreement is hereby amended and restated to read in its entirety as follows: 
 “(e) On the three-year anniversary of the Closing Date, all remaining Escrow Amounts minus the sum of (without duplication) the aggregate dollar amount of all indemnification claims pursuant to
Section 12.02(a) pending as of such date.” 
 10. Section 12.07(g) of the Transaction Agreement is hereby amended and restated to
read in its entirety as follows: 

  

	***	Material has been omitted pursuant to a request for confidential treatment and has been filed separately. 

 “(g) In no event shall any portion of the State FCA Settlement Amount remaining in the
Escrow Account be used to satisfy any obligations of Sellers hereunder other than payments to Governmental Authorities of the applicable states in accordance with Section 12.07(c).” 
 11. Buyer Domestic agrees that it will cause to be paid to JPMorgan Chase, N.A. and McKnight Title, on behalf of the Sellers, the amounts owed by Sellers to JPMorgan Chase, N.A., as specified in payoff
letters delivered by JPMorgan Chase, N.A. Such payment on behalf of Sellers shall be deemed payment to Sellers pursuant to Section 3.02(a)(iii) of the Transaction Agreement. 
 12. The parties acknowledge and agree that (i) the definition of “Retained Employee” shall be amended and restated to read in its entirety as follows: 

“Retained Employee” means ***.” 
 and (ii) the applicable Employment Agreement and Confidentiality, Non-Competition and Intellectual Property Assignment Agreement to which Maxwell Lea is party shall not be an “Assumed Employee
Agreement” and “Assumed Covenant Agreement”, respectively; provided, however, that the parties acknowledge that Buyer Domestic remains in discussions with Maxwell Lea regarding his employment status, and should Maxwell
Lea elect to become employed by Buyer Domestic or one of its Affiliates within 60 days following the Closing, the amendments set forth in this Section 12 (but, for avoidance of doubt, not the amendments contained in the remainder of this
Amendment) shall become null and void and shall be of no further force and effect. 
 13. At the Closing Buyer Domestic shall wire to
Healthpoint $***, representing Healthpoint’s estimate of 2012 bonuses that Buyer Domestic is obligated to reimburse pursuant to Section 10.05(f) of the Transaction Agreement and final December 2012 payroll (including payroll taxes) for the
period from December 15, 2012 through December 28, 2012. The parties agree that the portion of the final December 2012 payroll for the period through and including December 21, 2012 is an Assumed Liability (and shall be taken into
account in determining Closing Net Assets, without regard to the effect of the payment contemplated by this Section 13), and that the portion of the final December 2012 payroll for the period beginning on December 22, 2012 is being paid to
Healthpoint for administrative convenience to pay the Transferred Employees for the period from December 22, 2012 through and including December 28, 2012, and such amount shall not be an Assumed Liability (and shall not be taken into
account in determining Closing Net Assets). Following the Closing, Buyer Domestic and Healthpoint shall cooperate in reconciling such estimate to the actual amount of bonuses and payroll paid by Healthpoint, and if Healthpoint paid more than $*** in
respect of such matters, then Buyer Domestic shall pay such difference to Healthpoint, and if Healthpoint paid less than $*** in respect of such matters, then Healthpoint shall reimburse such difference to Buyer Domestic. Any dispute between Buyer
Domestic and Healthpoint with respect to such reconciliation shall be resolved by the Accounting Referee in accordance with the procedures set forth in Sections 3.04(c) and 3.04(d) of the Transaction Agreement. Buyer Domestic and Seller Parent
acknowledge that the 401(k) 

  

	***	Material has been omitted pursuant to a request for confidential treatment and has been filed separately. 

 
matching contributions for the year ended December 2012 cannot be computed until after December 31, 2012 and therefore will not be paid by Healthpoint on or before Closing, and that Buyer
Domestic shall reimburse Healthpoint for such matching contribution upon receipt of notice from Healthpoint that such payment has been made, which notice shall show in reasonable detail the calculation of such matching contribution. 

14. Buyer Domestic acknowledges and agrees that the letter granting an extension of the Transition Services Agreement among DPT Laboratories, Ltd.,
Renaissance Pharma (U.S.) Holdings, Inc., Renaissance SSP Holdings, Inc. and DFB Pharmaceuticals, Inc., dated as of June 29, 2012 (the “DPT TSA”), in the form provided by Sellers to Buyer Domestic prior to the date hereof, shall be
deemed to satisfy the closing condition specified in Section 11.02(d) of the Transaction Agreement relating to receipt of the Required Consent relating to the DPT TSA. 
 15. Ratification of Agreement. Except as expressly provided in this Amendment, all of the terms, covenants, and other provisions of the Transaction Agreement are hereby ratified and confirmed and
shall continue to be in full force and effect in accordance with their respective terms. From and after the date hereof, all references to the Transaction Agreement shall refer to the Transaction Agreement as amended by this Amendment. Capitalized
terms used but not defined in this Amendment shall have the meanings assigned to them in the Transaction Agreement. 
 16. Governing Law.
This Amendment shall be governed by and construed in accordance with the law of the State of Delaware, without regard to the conflicts of law rules of such state. 
 17. Execution of Agreement; Counterparts; Electronic Signatures. This Amendment may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Amendment shall become effective when each party hereto shall have received a counterpart hereof signed by all of the other parties hereto. Until and unless each party has received a
counterpart hereof signed by the other party hereto, this Amendment shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). In the event that
any signature is delivered by facsimile transmission, or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or “.pdf” format data file signature page were an original thereof. No provision of this Amendment is intended to confer any rights, benefits, remedies, obligations or liabilities
hereunder upon any Person other than the parties hereto and their respective successors and assigns. 
 [Signature Page to
Follow] 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the
date first above written. 
  

			
	DFB PHARMACEUTICALS, INC.
		
	 By:
	 	/s/ H. Paul Dorman
	 Name:  H. Paul Dorman

	 Title:  Chairman & CEO

	
	 SMITH & NEPHEW, INC.

		
	 By:
	 	/s/ Cyrille Petit
	 Name:  Cyrille Petit

	 Title:  Chief Corporate Development OfficerEX-4.(c)(iii)

 Exhibit 4 (c) (iii) 

Dated 07/11/2012 

EMPLOYMENT AGREEMENT 
 BETWEEN 
  

			
	(1)	  	SMITH & NEPHEW UK LIMITED
		
		  	And
		
	(2)	  	JULIE BROWN

 07/11/2012 
 PARTIES 
  

	(1)	Smith & Nephew UK Limited whose registered office is at 15 Adam Street, London WC2N 6LA (“We”) or (“Us”) 

 

	(2)	JULIE BROWN of 15 Adam Street, London WC2N 6LA (“You”) 

 

	A	This Agreement sets out the terms and conditions that apply to your employment with Us. We also have a staff handbook that contains provisions relevant to your
employment. If there is any conflict between that handbook and this Agreement, however, this Agreement prevails. 

  

	B	The final section of the Agreement sets out definitions and general provisions that apply throughout the Agreement. 

 

	C	Our offer of employment under this Agreement is conditional on the following: 

 

	 	(a)	You must have the right to work in the UK and have provided Us with the documentary evidence of this (e.g. Your passport) that We are required to have under the
Immigration, Asylum and Nationality Act 2006. If You do not have an unrestricted right to work in the UK, You are required to keep Us updated with any change to Your personal details and UK immigration status. We may provide Your data to the UK
Border Agency to enable Us to fulfil our legal obligations.. 

  

	 	(b)	You must not be subject to any restrictive covenants or other legal obligations which would prevent You from carrying out your job for Us. 

 

	 	(c)	You represent and warrant that You have complied with all appropriate legal obligations and have not been charged or (to your knowledge) investigated with regard to any
offence other than minor traffic violations or other, similar misdemeanours unrelated to Your work. In particular, You warrant that You have not been prohibited from being a director or been charged with any offence involving dishonesty or violence.
We will carry out a background check and Your employment is subject to a satisfactory response. 

  

	 	(d)	We receive satisfactory references with regard to your prior experience and employment history and satisfactory results to background searches.

 If these conditions are not satisfied and/or You have misled Us, then We have the right to terminate your
employment without notice within a reasonable period of Us discovering this. 
  

	D	You confirm that by entering into this Agreement and working for Us that You are not in breach of any obligation to any third party or of any court order.

  

	E	You also confirm that You have disclosed to Us in writing details of all previous criminal convictions (other than those that are spent). 

 INDEX 

 

			
	 Section
	 	 Description

	1	 	Your Job
	2	 	Your Remuneration
	3	 	Protecting the Company Whilst You Are Employed
	4	 	Discipline and Grievance
	5	 	Sickness and Absence from Work
	6	 	Termination of Employment
	7	 	Protecting the Company After Your Employment Has Ended
	8	 	Miscellaneous and General Provisions

 SECTION ONE: YOUR JOB 

 

	1.	THE APPOINTMENT 

  

	1.1	 You are employed by Us as Chief Financial Officer of Smith & Nephew plc from January 1st 2013 or such other date before or after that date being the earliest
date on which You are able to secure a release from your existing employment contract, which You shall use reasonable endeavours to achieve. For statutory purposes, You have been continuously employed by Us since the same date.

  

	1.2	We can make reasonable changes to your job title, your duties and responsibilities provided always that such changes do not diminish your status and responsibilities or
substantially alter the capacity and role in which You are employed. 

  

	1.3	You must comply with all of our rules, regulations, policies and procedures. 

 

	1.4	You must carry out all the assigned duties and functions consistent with your role; exercise all the powers and comply with all our instructions in connection with the
business that We reasonably require. You must use your reasonable endeavours to promote our interests. 

  

	1.5	If We ask You for any information or explanations about your employment or our business or affairs, You must give it to Us as soon as reasonably practicable (in writing
if required). 

  

	1.6	You must comply with any restrictions that We may properly impose on You or other executives. In particular, You must not without our written consent:

  

	 	(a)	Incur any capital expenditure or liability on our behalf in excess of the authorisation limits that have been set for you; and 

 

	 	(b)	Enter into any contract or obligation on our behalf that is outside the normal course of our business or your duties or is of an unusual, onerous or long-term nature.

  

	1.7	If We ask, You will accept any directorship, trusteeship or other position of responsibility in the Group that We may reasonably require which is generally consistent
with your role. 

  

	2.	HOURS OF WORK 

  

	2.1	Our normal office hours are currently 9 am to 5 pm Monday to Friday but You are expected to work whatever hours We reasonably require of You. 

 

	2.2	Unless You are off sick or on holiday, You must devote as much of your time, attention and skill to our business as We reasonably require. 

 

	2.3	We acknowledge that (as a managing executive) the duration of your working time is not measured or predetermined or You can determine it yourself. Nevertheless, if the
Working Time Regulations 1998 do govern your working hours, You agree that if We need You to do so that You will work in excess of an average 48 hour working week and that You therefore agree to opt-out of the 48 hour average limit set out in those
Regulations. If the law in future permits, You agree that your average working hours should be measured against whatever reference period We may reasonably decide should apply. 

	3.	PLACE OF WORK 

  

	3.1	Your normal place of work is 15 Adam Street, London, WC2N 6LA. Your normal place of work will not be moved from 15 Adam Street, London, WC2N 6LA without your prior
written agreement which shall not be unreasonably withheld if the new location is within reasonable commuting distance of your home at the time. However, We may require You to work elsewhere within the United Kingdom on a temporary basis; i.e. for a
period (or periods in aggregate) not exceeding two months in any calendar year. 

  

	3.2	You are required to travel in the UK, Europe or worldwide as part of your duties. 

 

	3.3	For the purposes of Part I of the Employment Rights Act 1996, it is not expected that You will be required to work outside the United Kingdom for more than one month at
a time. 

 SECTION TWO: YOUR REMUNERATION 

 

	4.	SALARY 

  

	4.1	Your basic annual salary is £500,000. The salary accrues daily and is payable in equal monthly instalments in arrears on or before the last working day of each
month. 

  

	4.2	Your salary will be reviewed not less than annually on or about 1 April. The first review date for You will be 1 April 2014. We are not under any obligation to
increase it at each review but it shall not be reduced. 

  

	4.3	There is no additional remuneration for any directorship, trusteeship or other position of responsibility that You may hold in the Group. 

 

	5.	SENIOR EXECUTIVE BONUS SCHEME 

  

	5.1	You will be eligible to participate in the Group Executive Bonus Scheme. Full details will be sent to You under separate cover. The Scheme is performance-based and for
target achievement the bonus payment is 100% of basic salary. The plan may be changed by the Remuneration Committee at any time. Any payment under the Plan is discretionary and there is no contractual entitlement to receive it. Bonus is not deemed
to be contractual remuneration for pension purposes or otherwise. 

  

	5.2	In recognition of the fact that you will be foregoing your short term incentive payment from AstraZeneca due in the early part of 2013 You will be provided with a
payment of £200,000 in April 2013 provided you accept the offer. The conditions attached to this award are attached in the enclosed letter. Furthermore, on joining Smith and Nephew, you will be provided with a payment with a net value of
£30,000 should AstraZeneca decide to recoup the relocation assistance provided. 

  

	5.3	In addition, You will be granted a conditional award over 75,000 shares as soon as practicable after your appointment, subject to close periods, in recognition of the
awards you will be foregoing from AstraZeneca. This award will vest in three equal tranches on the first, second and third anniversaries of the grant date as described in a separate agreement. 

	6.	EXECUTIVE SHARE INCENTIVE PLANS 

  

	6.1	You will be eligible to participate in the 2010 Global Share Plan, or any successor, at the discretion of the Remuneration Committee. Full details will be sent to
You under separate cover. The current entitlement comprises: 

 (a) An annual equity award
equivalent in value to between 50% (at target) and 65% (at maximum) of base salary depending on annual performance vesting, in annual equal tranches over a three year period; and 

(b) A performance share award equivalent in value to between 95% (at target) and 190% (at maximum) of base salary
vesting after three years subject to performance conditions related to TSR performance and free cash flow. 
  

	6.2	The first awards under these arrangements will be made in March 2013 

  

	6.3	The Remuneration Committee regularly reviews these incentive arrangements and the precise structure of these arrangements may change in future.

  

	7.	EXECUTIVE SHARE OWNERSHIP REQUIREMENTS 

  

	7.1	One of the main objectives of our suite of incentive plans is to ensure there is strong alignment between the interests of our senior executives, which includes You,
with those of our shareholders. Therefore, in order to encourage You to think like our shareholders, there is an expectation that You will build up and maintain an appropriate level of shareholding in Smith & Nephew plc as a consequence of
Your participation in the various incentive schemes operated by Us, whether referred to in this agreement or otherwise. The Remuneration Committee is currently reviewing the share ownership requirements and You will be bound by the share ownership
requirements once they have been finalised. . For the avoidance of doubt the conditional award over 75,000 shares detailed in 5.2 above will NOT be subject to the share ownership requirements. 

 

	8.	EMPLOYEE SHARE OPTION SCHEME 

  

	8.1	You will be eligible for the savings related Employee Share Option Scheme providing you have worked for the Group for three months prior to the relevant invitation
date. Invitations are usually made on an annual basis and full details will be sent to You under separate cover. 

  

	9.	COMPANY CAR 

  

	9.1	You will be provided with benefits in accordance with the Smith & Nephew UK Car Policy. Details of approved drivers and insurance cover are as follows:

  

	 	(c)	Approved drivers: Company cars may be driven by the designated company car driver, his / her spouse, children over 21, any other authorised nominated driver, and
any other Smith & Nephew employee who is a company car driver or is on the list of Approved Drivers. Nominated drivers must hold a valid full UK driving licence, and must have received prior company authorisation. 

It is a requirement that any employees entitled to a company car must sign a Driver Obligation Form prior to driving a company car.

 Any variation to the above arrangements can only be authorised by the Chief Executive Officer by written request. 

In all schemes (including but not limited to the Car Policy) referred to in this Agreement where there are provisions for a spouse, We
will use all reasonable endeavours to procure that the definition of spouse shall include your co-habiting partner. 

	 	(d)	Insurance cover: Employees are responsible for taking care of their assigned vehicle and its contents. 

The insurance policy arranged by the company covers all company car drivers, their spouses, and other authorised nominated drivers and
any children over 21, subject to the conditions above. All company cars are insured for comprehensive cover, including third party, fire and theft. A copy of the insurance certificate will normally be issued every year. 

The insurance cover relates only to company cars, and not to any other personal vehicle, whether or not being used on company business.

 Any personal loss will be covered only to a maximum of (under current policy) £100. Any claim above this amount should
be made through the employee’s home or personal insurance. 
 In the event of accidents, damage, theft or vandalism
occurring that is due wholly or in part to the employee’s negligence, then the employee may be subject to company disciplinary procedures. 
  

	 	(e)	The current company car lease value for your position is £900 per month. Examples of cars currently at this level are: 

BMW 535 DM Sport 
 Mercedes E350 
 Audi A8 

Lexus Rx400h 

You can trade-up, and down (in which case You would receive the difference between the car lease value and the actual cost of the vehicle
as cash less Tax and National Insurance). 
 If You select the option of a company car You will be reimbursed for the cost of
business and private mileage (except that used for annual holidays). Alternatively, You can receive a monthly petrol allowance, which under current policy is £100 less tax and national insurance. 

 

	 	(f)	Company car cash alternative: You will be eligible to choose cash payments as an alternative to a company car. The Cash Alternative value for your position is
£13,440. The allowance is not pensionable, but is subject to tax and national insurance. Each cash alternative “contract” will last for a minimum period of 12 months. 

You are entitled to reimbursement of petrol costs for business and private mileage (unless incurred during any holiday period) as if You
had opted for a company car. This is paid at the prevailing standard reimbursement rate through payroll, less tax and national insurance. 
  

	10.	PENSIONS, LIFE ASSURANCE AND INCOME PROTECTION 

  

	10.1	Pensions, Life Assurance and Income Protection policy is subject to continuous review by the Board of Smith & Nephew plc and the Remuneration Committee and may
be amended from time to time at their discretion. However, You shall be eligible for cover under any such schemes or policies from time to time in force for the benefit of directors and senior executives. 

	10.2	Pension Plan  

 You will
be able to choose between: 
 a company contribution to the Smith & Nephew Stakeholder Pension Plan (the
“Stakeholder Pension Plan”) of 30% of basic salary; 
 or 

a cash supplement of 30% of basic salary. 
 Your decision may then be reviewed annually on a tax year basis. Please note that the cash supplement will be non-pensionable and non-bonusable. 

You can elect to contribute to the Stakeholder Pension Plan up to any applicable HM Revenue & Customs limits from time to time in
force. 
 The Company reserves the right to change the basis or level of its contributions to the Stakeholder Pension Plan or
cash supplement upon giving You reasonable notice of its intention to do so and, in the event of a reduction in the level of its contributions, without having to provide any benefit or compensation in lieu thereof. 

The Company also reserves the right to terminate your ongoing participation in the Stakeholder Pension Plan or the payment of the cash
supplement. 
 The Stakeholder Pension Plan will be a designated stakeholder pension scheme in accordance with the Welfare Reform
and Pensions Act 1999 and the regulations made under it. 
 No contracting out certificate is in force in relation to your
employment. 
  

	10.3	Life Assurance  

 In
addition to the company contribution to the Stakeholder Pension Plan (or salary supplement), We will also provide You with life assurance cover under the Smith & Nephew Stakeholder Group Death in Service Plan (the “Death in Service
Plan”). The cover is provided through an insurance company (the “relevant insurer”). The benefit provided on death in service is (subject to the terms of the relevant insurer) 7 x base salary, of which 4 x will be paid as a lump
sum to your dependants and 3 x will be used to purchase a pension for your dependants. 
  

	10.4	Income Protection  

Subject to the provisions below, We will make provision for an Income Protection Plan provided by an insurance company (the “relevant
insurer”) offering an income protection benefit, whilst You are an employee, of 75% of base pay (including any State Invalidity Benefits) in the event that You are unable to work due to sickness or injury after an initial period of absence of
52 weeks. 
  

	10.5	 Your participation in the Income Protection Plan is subject always to the rules of the relevant insurer’s scheme for the time being in force
(details of which are available from Human Resources) and to the approval of the relevant insurer. In the event that 

 
the relevant insurer declines to provide or continue to provide benefits, as the case may be, under the Income Protection Plan, we shall not be liable to provide any benefit or compensation in
lieu thereof. Further, we shall be entitled at any time (after giving you reasonable notice and reasonable assistance in implementing alternative arrangements) to terminate the Income Protection Plan or the Death in Service Plan or your
participation in it and/or to withdraw or change the rules or benefits of the Income Protection Plan or the Death in Service Plan provided that such variation withdrawal or termination applies to all our employees who are employed at a comparable
level to you, in which case we shall not be liable to provide any benefit or compensation in lieu thereof. It is a condition of your participation and continuing participation that you agree to undergo any medical examinations that might be required
from time to time. 
 Further details regarding the Stakeholder Pension Plan, the Death in Service cover and the Income
Protection Plan will be sent to you under separate cover. 
  

	11.	PRIVATE MEDICAL INSURANCE 

  

	11.1	Private health cover on London scale benefits is provided from the date of joining for yourself, and if applicable, your spouse and any of your unmarried children who
are under age 21 (or under age 24 if in full-time education). Full details will be sent under separate cover. 

  

	12.	HOLIDAYS 

  

	12.1	Our holiday year runs from 1 January to 31 December. In addition to bank holidays, You are entitled to 25 days’ paid holiday in each holiday year.

  

	12.2	Holidays accrue pro-rata in each holiday year. 

  

	12.3	Holidays must be taken at times agreed with your Manager. Holidays may not be carried forward from one holiday year to the next without our approval. There is no pay in
lieu of untaken holiday at the end of the holiday year. 

  

	12.4	We may decide whether or not any holiday that You have taken forms part of your entitlement under the Working Time Regulations. Unless We decide otherwise, it is
assumed that holidays accruing under those Regulations are taken first. 

  

	12.5	It may be necessary to set aside a certain number of days each year to cover the closure of the office at the Christmas and New Year periods and You will be informed if
this is the case. 

  

	13.	EXPENSES 

  

	13.1	We will reimburse You for all business expenses that are properly and reasonably incurred and claimed by You in accordance with our expenses policy. Expense claims must
be supported by whatever receipts or vouchers We require. 

  

	13.2	If We make a company credit card available to You, You must: 

  

	 	(g)	Take good care of it and immediately report if it is lost or stolen; 

  

	 	(h)	Only use the card for our business and in accordance with any applicable policy; and 

 

	 	(i)	Surrender it immediately on our request. 

 SECTION THREE: PROTECTING THE COMPANY WHILST YOU ARE EMPLOYED 

 

	14.	GENERAL DUTIES 

  

	14.1	At all times during your employment (including any period of suspension or while on garden leave) You are subject to a duty of goodwill, trust and confidence, exclusive
service and good faith towards Us. Without limitation, these duties require that You must not: 

  

	 	(j)	compete with the Group; 

  

	 	(k)	make preparations (during hours when You are required to work) to compete with the Group after your employment has terminated; 

 

	 	(l)	solicit business from customers or potential customers of the Group; 

  

	 	(m)	encourage employees to leave employment with the Group against the Group’s wishes; and/or 

 

	 	(n)	copy information relating to the Group for a purpose other than for the benefit of the Group. 

 

	14.2	If You are appointed as a director of a board of any Group Company, You must notify that board immediately if You act (or omit to act) in a way that may amount to a
breach of your obligations to the Group or if You become aware of or suspect any wrongdoing on the part of Group staff or contractors or any acts (or omissions) of third parties which might reasonably be expected to be harmful to the Group.

  

	15.	OTHER INTERESTS 

  

	15.1	You must devote all of your working time to the Group. You must not undertake any activity or do anything that might reasonably be expected to affect the full and
proper performance of your duties unless We agree first. Without limitation, You must not undertake any other employment or hold any other office without our prior formal agreement (such agreement not to be unreasonably withheld).

  

	15.2	You may invest in publicly traded competitors or suppliers, provided the investment is minimal in relation to your net worth, and is formally pre-authorised by the
Chief Executive Officer. Ownership of a substantial amount of stock, however, in a publicly traded competitor or ownership of an interest in a privately held company that competes with Smith & Nephew is prohibited. 

 

	15.3	You confirm that You have informed Us (and will continue to keep Us informed) of any conflict that may exist between your (or your immediate family’s) interests
and those of the Group. 

  

	15.4	You are not entitled to receive any discount, rebate, commission or other benefit in respect of business carried out by the Group (whether carried out by You or not)
and You must immediately disclose to and account to Us for any such benefit if You do receive it. 

  

	15.5	You must comply with our Code of Conduct at all times. 

	16.	MARKET ABUSE AND INSIDER DEALING 

  

	16.1	The freedom of Directors and certain employees to deal in the Company’s shares and ADRs is restricted in a number of ways including by UK statute, requirements of
the London and New York Stock Exchanges and US Federal Securities laws. As a result, the Company has adopted the Smith & Nephew Code of Dealing (the “Code of Dealing”) which is based on the UK Listing Authority’s Model Code
for Dealing in Securities. 

  

	16.2	The Dealing Code imposes restrictions to ensure that Directors, designated insiders and persons connected with them don’t abuse, or place themselves under
suspicion of abusing, price sensitive information especially in periods leading up to an announcement of results or potential acquisitions or disposals of part of the business. 

 

	16.3	In view of your position You are considered to be a designated insider and a copy of the Code of Dealing will be sent to You under separate cover. You will be required
to confirm that You have read and understood the Code of Dealing. 

  

	16.4	Any queries in relation to the Code of Dealing should be addressed to the Company Secretary, Smith & Nephew plc, 15 Adam Street, London WC2N 6LA.

  

	17.	CONFIDENTIAL INFORMATION 

  

	17.1	During the course of your employment, You will be exposed to information that is secret, confidential or commercially sensitive and which (if disclosed or used for
purposes other than those of the Group) could cause significant harm to the Group. In this Agreement, that information is referred to as Confidential Information and includes without limitation: 

 

	 	(o)	research and development carried out by the Group (whether or not that research is complete and including the outcome of any clinical or field trials) and potential
areas of research and development identified by the Group; 

  

	 	(p)	details of any applications for regulatory approval or clearance for any products or services developed by the Group; 

 

	 	(q)	the Group’s intellectual property (except where this is not protected by patent or equivalent protection); 

 

	 	(r)	the Group’s manufacturing techniques and methods and ideas for manufacturing techniques and methods; 

 

	 	(s)	the Group’s marketing and sales strategies and plans; 

  

	 	(t)	potential acquisitions and disposals by the Group; 

  

	 	(u)	the Group’s financial and sales performance; 

  

	 	(v)	information relating to the Group’s employees and contractors including without limitation their perceived strengths and weaknesses, remuneration and contact
details. 

  

	17.2	You must not use, disclose or permit to be used or disclosed (other than in the performance of your duties or as required by law) any Confidential Information. This
restriction applies both during the course of your employment and following its termination except in relation to Confidential Information which has come into the public domain other than by virtue of a breach of duty by You.

	17.3	You acknowledge that in the ordinary course of your employment, You will have access to Inside Information. You agree that all Inside Information is confidential and
must not be used, disclosed or permitted to be used or disclosed except as may be necessary for the proper performance of your duties to Us and in accordance with the requirements of the Market Abuse Directive or the law. 

 

	17.4	We are conscious that You will have been provided with and had access to confidential information relating to Your previous employment. You agree that You have not and
will not use any information of a confidential nature that is the property of Your previous employer (except where such information is already in the public domain) for the benefit of Us or our clients or customers. Such practice could expose Us to
legal action and could lead to Your summary dismissal. If You have any concerns or questions about the appropriateness of the use of any information which may be of a confidential nature, You should raise this with Human Resources/the Legal
Function. 

  

	17.5	The provisions of this Agreement are without prejudice to any duties and obligations of confidentiality to which You may be subject at common law or equity.

  

	17.6	You must not make or issue any press statement or give any interview to a journalist or publish or submit for publication any article or opinion relating directly or
indirectly to the Group without our prior agreement. 

  

	17.7	You must not at any time make any untrue or misleading statement in relation to the Group. 

 

	18.	INTELLECTUAL PROPERTY 

  

	18.1	Due to the nature of your duties and your particular responsibilities, You recognise that You have a special obligation to further the interests of the Group.

  

	18.2	You must disclose to Us at once any idea or invention created in the manner prescribed by sections 39(1) and 39(2) of the Patents Act 1977. Any such inventions will
then be dealt with in accordance with the provisions expressed in that Act. 

  

	18.3	You acknowledge that all trademarks, registered designs, design rights, copyright, database rights and other intellectual property rights (together, where registrable
with the right to apply for registration of those rights, aside from those described in Clause 15.2) will vest in and be our exclusive property or any of the Group Companies which We nominate if they come into existence during the normal course of
your employment or by using materials, tools or knowledge made available through your employment. This applies regardless of whether those rights are in existence now or come into existence at any time in the future. If required to do so (whether
during or after the termination of your employment), You must sign any document and do anything necessary to vest ownership in these rights in the Group as sole beneficial owner. Where ownership does not automatically vest by Act of Parliament, You
must immediately assign all your interests to the Group. You irrevocably waive all your rights pursuant to sections 77 to 83 inclusive of the Copyright Designs and Patents Act 1988. 

SECTION FOUR: DISCIPLINE AND GRIEVANCE 
  

	19.	You must comply with our disciplinary rules. Failure to do so is a serious breach of this Agreement. A copy of our disciplinary rules may be obtained from Human
Resources. 

	20.	The disciplinary procedure is referred to in the staff handbook. That procedure does not form part of this Agreement nor does it give rise to any contractual
rights as between You and the Group. If You are dissatisfied with any disciplinary decision taken against You, You may appeal to the Chairman of the Board of Smith & Nephew plc within 5 working days. 

 

	21.	If You have any grievance relating to your employment, You should raise it in the first instance with the Chief Executive Officer in accordance with our
grievance procedure. 

  

	22.	We have the right to suspend You with full pay and benefits at any time to allow Us to conduct a disciplinary investigation or if your dismissal is being
contemplated. Suspension may be for such period as is reasonably necessary in the circumstances and shall not normally exceed 7 days. 

 SECTION FIVE: SICKNESS AND ABSENCE FROM WORK 
  

	23.	INCAPACITY 

  

	23.1	If You are unable to attend work due to sickness or accident, You must inform your Manager the first morning of absence, or as soon as is reasonably possible.

  

	23.2	If your absence is for a period of 1 working day or more You will need to provide a self-certification form, obtainable from the Human Resources Department. This will
cover You for a maximum of 7 calendar days, after which a doctor’s statement is required. 

  

	23.3	If You are absent from work owing to illness or injury You will be entitled to salary during the period of absence in accordance with the following scale. All such
payments will be subject to deduction of Statutory Sick Pay or National Insurance Sickness Benefit receivable. 

  

			
	 Length of Continuous Service
	  	 Payment entitlement in any 12 month period

		
	 0 - 3 years
	  	6 months full pay
 6 months half
pay

		
	 After 3 years
	  	12 months full pay

  

	23.4	Your sick pay entitlement is based on your service at the beginning of the sickness period. 

 

	23.5	The table set out in 23.3 also indicates the maximum sick pay entitlement payable in respect of one period of continuous absence as determined by our standard Company
policy. This policy statement should be read in conjunction with Clauses 10.5 and 10.6 (Income Protection) which in your case may provide a higher level of benefit. 

 

	23.6	Your entitlement to salary under the Company’s sick pay scheme includes any benefit from the Income Protection Plan where appropriate. 

 

	23.7	At our request You will agree to undergo a medical examination performed by a doctor appointed and paid for by Us. You authorise the Board and the board of
Smith & Nephew plc to have access to any reports produced as a result of that examination provided that You are also shown copies of the same. 

 SECTION SIX: TERMINATION OF EMPLOYMENT 

 

	24.	NOTICE 

  

	24.1	We have to give You six months’ notice in writing to terminate your employment in the first year and twelve months’ notice in writing thereafter.

  

	24.2	If You want to resign, You must give Us three months’ notice in writing in the first year of your employment and six months’ thereafter.

  

	24.3	We may terminate your employment immediately and without any entitlement to notice under 24.1 or compensation if: 

 

	 	(w)	You are guilty of gross misconduct or gross negligence; 

  

	 	(x)	without reasonable cause, You neglect, omit or refuse to perform all or any of your duties or obligations under this Agreement or You fail to any substantial or
material extent to observe and perform the provisions of this Agreement to our reasonable satisfaction provided always that where such matters are capable of remedy, We shall not terminate pursuant to this clause unless and until We have given You
28 days’ written notice of the relevant matter requiring You to remedy the same and You have failed to do so; or 

  

	 	(y)	You misconduct yourself whether during or outside the course of your duties under this Agreement in such a way that in our reasonable opinion our business, operation,
interests or reputation of that of the Group are or are likely to be prejudicially affected, provided always that where such misconduct is capable of remedy so as to avoid such prejudicial effect We shall not terminate pursuant to this clause unless
and until We have given You 28 days’ written notice of the misconduct requiring You to remedy the same and You have failed to do so; or 

  

	 	(z)	You commit any criminal offence (including in particular any offence involving dishonesty or violence) other than an offence which does not in our reasonable opinion
affect your position under this Agreement; or 

  

	 	(aa)	You commit an offence under any statutory enactment or regulation or any provision of this Agreement relating to insider dealing or market abuse (whether that enactment
was passed in the United Kingdom or United States of America or elsewhere); or 

  

	 	(bb)	You become bankrupt or make or attempt to make any composition with your creditors; or 

 

	 	(cc)	You become prohibited by law from being a director of a company or You cease to be a director of a Group Company without our consent or concurrence; or

  

	 	(dd)	You are guilty of any deliberate act of discrimination, harassment or victimisation on grounds of race, sex, disability, sexual orientation, religion/religious belief
or age. 

	25.	GARDEN LEAVE 

  

	25.1	During any period of notice, and provided that We continue to pay your salary and provide the benefits (other than bonus) to which You are entitled under this Agreement
until your employment terminates, then We are entitled at our absolute discretion during the remaining period of your notice period (or any part of such period) to place You on garden leave You will be deemed to have taken any accrued but untaken
holiday during any period of garden leave. This means that We may require You: 

  

	 	(ee)	not to carry out all or part of your duties or to exercise your powers or responsibilities under this Agreement or require You to carry out alternative duties;

  

	 	(ff)	to resign immediately from any offices You may hold with the Group; 

  

	 	(gg)	not to attend your place of work or any other Group premises; 

  

	 	(hh)	not to have contact (including socially) with any suppliers or customers of the Group or with employees (other than socially) except as authorised by Us;

  

	 	(ii)	to return to Us all documents, computer disks and other property (including summaries, extracts or copies) belonging to the Group or to its or their customers;

  

	 	(jj)	to work from your home and/or to carry out exceptional duties or special projects outside the normal scope of your duties and responsibilities provided always that such
special projects are appropriate to your status, skills and experience; and/or 

  

	 	(kk)	to take or not to take all or part of any outstanding holiday during your notice period. 

 

	25.2	You will have no entitlement to bonus in respect of any period of garden leave but the Remuneration Committee may, in its absolute discretion, determine to pay You a
sum in respect of bonus in respect of such period. 

  

	25.3	In the event that it is agreed that any period of garden leave should come to an end and your employment terminate to allow You to commence employment elsewhere, all
payments to You would then cease and You would have no right to compensation in respect of any outstanding period of notice. 

  

	26.	CORPORATE GOVERNANCE AND PHASED PAYMENTS 

  

	26.1	Following a decision to terminate your employment (except in the circumstances defined under 24.3) the Remuneration Committee may use its discretion to determine not to
require You either to work out your notice period in full (as provided for in Clause 24.1 above) nor to place You on garden leave (as provided for in Clause 25 above). In such circumstances the Remuneration Committee will pay a sum equivalent to all
of the salary and benefits (excluding bonus) You would have received if We had required You to work during your notice period. You will have no entitlement to bonus in respect of any period of notice which You have not worked but the Remuneration
Committee may, in its absolute discretion, determine to pay You a sum in respect of bonus in respect of such period. 

  

	26.2	 In deciding whether to exercise any discretion under Clauses 25.2 and 26.1, the Remuneration Committee will take into account all relevant
circumstances including the Group’s policy not to “reward for failure”, the appropriateness of your obligation to mitigate for loss, and other relevant “corporate governance” guidelines.

	27.	OTHER TERMINATION PROVISIONS 

  

	27.1	Nothing in this Agreement shall prevent Us from terminating your employment on grounds of ill-health if You are unable through health reasons (in circumstances of at
least 26 week’s absence) to perform your duties even though at the time your employment terminates You have not exhausted your full sick pay entitlement or the consequence of the termination would be to end your entitlement to any further
payments under the Income Protection Plan. 

  

	27.2	On termination of your employment, your entitlement to accrued holiday pay will be calculated pro-rata. If You have untaken holiday due under the Working Time
Regulations on the date your employment terminates, You will be entitled to pay in lieu of that untaken holiday (save that if You are dismissed for gross misconduct or gross negligence then that pay in lieu will be calculated at the rate of
£1 per day). 

  

	27.3	If your employment terminates, You agree that You will immediately (at our expense) transfer all shares held by You as a result of our asking You to hold them on our
behalf, either in trust or as a nominee, to whatever persons We direct. 

  

	27.4	On termination of your employment (or earlier if requested), You will immediately return to Us all Group property in your possession or control (without keeping any
copies). This obligation extends to any copies, drafts, notes, extracts or summaries (however stored or made) of all documents and software that relate to the Group’s business. If You have stored or copied any of the Group’s data or
information onto a computer, personal organiser or other electronic storage device which does not belong to the Group then You must immediately irretrievably delete that data or information and must allow Us to have access to that device to verify
that the data or information has been deleted. 

  

	27.5	You will immediately on termination of your employment or at any other time on request of the Board, resign immediately without claim for compensation as a director of
any Group Company or from any trusteeship, office or appointment held by You on behalf of the Group. 

  

	28.	CHANGE OF CONTROL 

  

	28.1	In a change in control situation affecting Smith & Nephew plc the entitlements set out below would be payable where within 12 months of that change there is a
significant diminution of role or status, a reduction in salary or benefits, or a mandatory relocation (the so-called “double trigger” scenario) and where termination by employer or employee is a consequence of such a change in control.

  

	 	•	 	 Normal twelve months base salary payable as a lump sum 

 

	 	•	 	 The Remuneration Committee will consider to what extent an annual bonus award should be made in the change of control circumstances

  

	 	•	 	 Lump sum in lieu of 12 months car benefits and healthcare benefits based on current provision costs 

 

	 	•	 	 Lump sum in lieu of 12 months pension contribution or salary supplement, as appropriate 

 

	 	•	 	 Reasonable executive outplacement costs 

	28.2	In a change in control situation affecting Smith & Nephew plc entitlement under the and the Group’s share plans will be in accordance with the Rules of
each of those Plans. 

  

	28.3	These change in control terms supersede the notice terms and entitlement set out in the Termination of Employment section. 

SECTION SEVEN: PROTECTING THE COMPANY AFTER YOUR EMPLOYMENT HAS ENDED 

 

	29.	CONFIDENTIALITY 

  

	29.1	The confidentiality provisions set out in Clause 17 continue to apply to protect Confidential Information following the termination of your employment.

  

	30.	RESTRICTIVE COVENANTS 

  

	30.1	At any time in the period set out in Column A below, You must not carry out the activities set out in Column B. The Column B activities, however, are subject to the
provisos and limitations set out in Column C. 

  

					
	 A

(Restricted
Period)
	  	 B (Restricted Activity)
	  	 C (Provisos and Limitations)

	12 months from the date your employment with Us ends	  	Accepting employment with or engaging, assisting or being interested in any undertaking which carries out research, development or manufacturing of products or services in the
fields of, orthopaedics, endoscopy and/or wound management and/or biologics related to the above.	  	This restriction only applies where: (a) You were materially concerned with research, development or manufacturing of that type during the last 12 months of your employment; and (b)
that undertaking competes with the Group.
			
	12 months from the date your employment with Us ends	  	Accepting employment with or engaging, assisting or being interested in any undertaking which carries out marketing and/or selling of products or services in the fields of,
orthopaedics, endoscopy and/or wound management and treatment and/or biologics related to the above.	  	This restriction only applies where: (a) You were materially concerned with marketing and selling of that type during the last 12 months of your employment; and (b) that undertaking
competes with the Group; and (c) that marketing or selling takes place in a Prohibited Territory.
			
	12 months from the date your employment with Us ends	  	Soliciting orders from or being concerned with the supply of orders to any person who is a customer of the Group.	  	This restriction only applies where: (a) the orders would be supplied in a Prohibited Territory; (b) the orders relate to the supply of products or services in the fields of
biologics, orthopaedics, endoscopy and/or wound management; (c) the orders are in competition with the Group; (d) that person was someone with whom (during the last 12 months of your employment) You had personal contact or were materially concerned
or about whom You possessed confidential information; and (e) that person had been a customer in the last 12 months of your employment. The expression “customer” includes a prospective
customer.

					
	12 months from the date your employment with Us ends	  	Interfering or trying to interfere with the continuance of supplies to the Group or the terms on which those supplies are provided	  	This restriction only applies if the supplier is a person with whom (during the last 12 months of your employment) You had personal contact or were materially concerned or about
whom You possessed confidential information.
			
	 12 months from the date your

employment with Us ends
	  	Offering employment to an employee of the Group or persuading an employee to leave the Group.	  	This restriction only applies if: (a) the employee is engaged in an executive, managerial, sales, research or development role; and (b) during the last 12 months of your employment,
You had personal contact or were materially concerned with or possessed confidential information about the employee. The expression “employee” includes consultants, non-executive directors and contractors. It is immaterial whether or not
the employee leaves the Group in breach of contract.

  

	30.2	These covenants prevent You from doing the restricted activities yourself or in any other way. You must not do them through others acting on your behalf or on your
instructions or with your encouragement. You must not do them whether they are for your benefit or not. 

  

	30.3	The duration of these restrictive covenants shall be reduced by an amount equal to the time that You may be placed on garden leave by Us in accordance with Clause 25.

  

	30.4	The expression in Clause 30.1 the “last 12 months of your employment” excludes any time spent by You on garden leave. 

 

	30.5	The expression “Prohibited Territory” means: 

  

	 	(ll)	In North and South America - Canada, Mexico, Puerto Rico and the United States 

 

	 	(mm)	In Europe - Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Eire, Estonia, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands,
Norway, Portugal, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom 

  

	 	(nn)	In Asia - Brunei, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand

  

	 	(oo)	In Australasia - Australia, New Zealand 

  

	 	(pp)	In Middle East - United Arab Emirates 

  

	 	(qq)	In Africa - South Africa, 

 as
well as any other country in which (at the date your employment terminates) the Group markets or sells products or services directly or via a distributor or agent. 
  

	30.6	If the business of the Group expands beyond the fields of biologics, orthopaedics, endoscopy and wound management/treatment then the restrictive covenants will also
apply to protect those new fields of activity. 

	30.7	If You apply for or are offered a new employment, appointment or engagement, You must immediately bring the terms of this Agreement to the attention of the person to
whom You are applying or the person making that offer. 

 SECTION EIGHT: MISCELLANEOUS AND GENERAL PROVISIONS

  

	31	DEFINITIONS 

  

	31.1	In this Agreement, the following words have the following meanings: 

  

			
	Board	  	Our Board of Directors from time to time and any person or committee authorised by the Board to act as its representative for the purposes of this Agreement
		
	Chief Executive Officer	  	The Chief Executive Officer of Smith & Nephew plc
		
	Group Company	  	Smith & Nephew plc and its subsidiaries and any holding company and the other subsidiaries of that holding company (as those expressions are defined in the Companies Act 1985)
together with any associated company (which means any other company in which We or our holding company or any subsidiary of ours or our holding company beneficially holds not less than 20% of the equity share capital), and Group is All or any of the
Group Companies.
		
	Remuneration Committee	  	The sub-committee of the board of Smith & Nephew plc comprising non-executive directors, responsible for setting (inter alia) the pay and benefits of the executive directors of
Smith & Nephew plc and executive officers of the Group.

  

	31.2	Any reference to a statutory provision includes all re-enactments and modifications of that provision and any regulations made under it or them.

  

	31.3	The headings in this Agreement are for convenience only. They do not form part of this Agreement and do not affect its interpretation. 

 

	31.4	Any reference in this Agreement to You, if appropriate, includes your personal representatives. 

 

	31.5	Any reference in this Agreement to We or Us includes any Group Company if the context requires or if We so decide. 

 

	32.	GENERAL PROVISIONS 

  

	32.1	Any provision in this Agreement which confers any rights or powers means those rights or powers as exercised by Us from time to time. Those rights or powers may be
exercised by the Board or by any other person acting on our behalf and within the scope of their authority. 

  

	32.2	Any reference to any rule, regulation, policy, procedure or scheme means the rule, regulation, policy, procedure or scheme that is in force and as amended from time to
time. 

  

	32.3	 Any rule, regulation, policy, procedure or scheme referred to in this Agreement may be varied (in whole or part) or cancelled or terminated by Us at
any time. We are not obliged to give any prior warning before making that variation, cancellation or termination nor are We under any obligation to compensate You for that variation, cancellation or termination, even if You are disadvantaged
(financially or otherwise) 

	 	
as a result. We are not obliged to substitute a replacement rule, regulation, policy, procedure or scheme but, if We do provide a substitute, it may be on whatever terms We consider appropriate
provided always that You shall be treated no less favourably than other senior executives of comparable status to yourself under those terms. The duty of trust and confidence shall not extend to any exercise by Us of the rights and powers contained
in this clause. 

  

	32.4	If any scheme provider (not limited to an insurance company) or other third party refuses for any reason to provide any benefit which is set out in this Agreement (or
to provide any benefit on terms that We consider to be reasonable) in relation to You or if applicable to your spouse, partner or children then We are not liable to make any payment; provide any replacement benefit or pay compensation in lieu of
that benefit. We may in our discretion challenge any refusal (and shall not unreasonably refuse your request for such a challenge) by any scheme provider or other third party to provide benefits but, if We do, it is on condition that:

  

	 	(rr)	You take all proper measures to appeal against the refusal in accordance with any applicable scheme and meet all reasonable costs associated with that appeal;

  

	 	(ss)	You co-operate fully with Us and disclose all relevant personal information; 

 

	 	(tt)	If required, You attend a medical examination with one or more medical practitioners selected and instructed by Us; and 

 

	 	(uu)	You indemnify Us fully against all reasonable costs, expenses and claims incurred by Us in connection with challenging that refusal. 

 

	32.5	Any provision of this Agreement which says that You must not do something means that You must not do it yourself or in any other way. You must not do it through others
acting on your behalf or on your instructions or with your encouragement. 

  

	32.6	You agree to comply with all our policies and procedures including without limitation our email and internet policy and data protection policy.

  

	32.7	Nothing in this Agreement confers any rights on your spouse, dependants, relatives or any third party except that, for the purposes of the Contracts (Rights of Third
Parties) Act 1999, the Group can enforce the restrictive covenants, confidentiality, intellectual property clauses and any other clause of this Agreement that purports to confer rights on the Group in relation to You. 

 

	32.8	Any delay by the Group or You in exercising any of its rights under this Agreement will not constitute a waiver of those rights. 

 

	32.9	You appoint Us to be your attorney (in your name and on your behalf) to execute any instrument or do anything necessary for the purpose of giving to Us or our nominee
the full benefit of the provisions of Clauses 18, 27.3 and 27.5 of this Agreement. You acknowledge in favour of any third party that a certificate in writing, which is signed by any director or secretary of the Board, or of the board of
Smith & Nephew plc, stating that any instrument or act falls within the authority conferred shall be conclusive evidence that such is the case. 

	33.	DEDUCTIONS 

  

	33.1	You authorise Us at any time during your employment or following its termination (whether or not that termination is lawful) to deduct from your wages (as that
expression is defined in the Employment Rights Act 1996) any monies due from You to the Group, including without limitation the outstanding balance of any loan account; the cost of repairing any damage or loss to Group property caused by You; any
overpayment of holiday pay; and any loss suffered by the Group as a result of any breach of contract, statutory duty or tort committed by You. 

  

	34.	DATA PROTECTION 

  

	34.1	You consent to Us processing personal data about You for the purposes of the Data Protection Act 1998. 

 

	34.2	You agree to use all reasonable endeavours to keep Us informed of any changes to your personal data and to comply with the Data Protection Act 1998.

  

	35.	COLLECTIVE AGREEMENTS 

  

	35.1	There are no collective agreements with trade unions that directly affect your terms and conditions of employment. 

 

	36.	NOTICES 

  

	36.1	Any notice to be given under this agreement shall be in writing. Notices may be delivered by hand; sent by first-class post or email. In your case, a notice will be
deemed to have been validly served if it is sent to the last address that You have notified to Us as being your address. In our case, any notice should be addressed to the Company Secretary of Smith & Nephew plc and should be sent to the
registered office address or to their personal email address. 

  

	36.2	Any notice served by post will be deemed to have been served 48 hours after it was posted or in the case of email, 1 hour after it was sent. 

 

	37.	TERMINATION OF PREVIOUS AGREEMENTS 

  

	37.1	This Agreement, together with any other documents referred to in this Agreement, constitutes the entire agreement and understanding between the parties, and supersedes
all other agreements both oral and in writing between You and us which shall be deemed to have been terminated by mutual consent as from the date of this Agreement. 

 

	37.2	You acknowledge that You have not entered into this Agreement in reliance upon any representation, warranty or undertaking which is not set out in this Agreement or
expressly referred to in it as forming part of your contract of employment. 

  

	38.	CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

  

	38.1	A person who is not a party to this Agreement shall have no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any of its terms.

  

	39.	GOVERNING LAW AND JURISDICTION 

  

	39.1	This Agreement is governed by and interpreted in accordance with English law. 

 

	39.2	 The parties submit to the non-exclusive jurisdiction of the High Court of England and Wales in connection with any claim, dispute or matter arising out
of relating to this Agreement. 

 IN WITNESS of which the parties have executed this Agreement on the date set out above. 

 

					
	EXECUTED AS A DEED	 		 	SIGNED and delivered as a deed by
	Director/Secretary	 		 	JULIE BROWN
			
	 /s/ Helen Maye
	 		 	 /s/ Julie Brown

			
	Signature:	 		 	Signature:
			
		 		 	in the presence of
			
	Name: Helen Maye (Authorised Signatory)	 		 	Signature of Witness: /s/ R.D. Newcomb
			
		 		 	Name: R.D. Newcomb
			
		 		 	Address of Witness:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}]]